Charles River says new innovation lab will be open in “early 2020”
Charles River Laboratories, a provider of laboratory services for the pharmaceutical, medical device, and biotech industries, has announced that it’s opening a new south San Francisco accelerator and development lab (CRADL) early next year. The company says that the new lab will provide “flexible, turnkey vivarium rental space supported by Charles River’s technical, vivarium, and veterinary support expertise in key biohubs.”
Charles River Laboratories’ share price has risen by 22% so far this year
Source: Yahoo Finance
The intention is simple: to provide specialist research areas to players in pharma and biotech, and empower them with the full range of Charles River’s integrated drug discovery services – a powerful set of innovative tools. The company continued to describe the rentals, saying: “managed by skilled technicians, every research model receives best-in-class care in secure, modern, regulatory-compliant facilities.”
In providing this service, Charles River is building on the success of a similar setup in Cambridge, Massachusetts, which will act as CRADL’s sister facility.
In a statement, the company’s corporate executive vice president for discovery and safety assessment, biologics testing solutions and avian vaccine services, Birgit Girshick, said: “In the earliest days of research, reaching key milestones on time and on budget is paramount to a program’s success. CRADL offers researchers the ability to focus on their research. When clients are ready to progress their idea through the development pipeline, Charles River has the portfolio and scientific expertise to offer critical support.”
Dominion holds Charles River Laboratories in its Global Trends Managed Fund.
If you would you like to receive the Newsfeeds daily, please click here to sign up now!Help us make this Newsfeed better by rating this article. 1 star = Poor and 5 stars = Excellent
- Click here to print this story: Print
The views expressed in this article are those of the author at the date of publication and not necessarily those of Dominion Fund Management Limited. The content of this article is not intended as investment advice and will not be updated after publication. Images, video, quotations from literature and any such material which may be subject to copyright is reproduced in whole or in part in this article on the basis of Fair use as applied to news reporting and journalistic comment on events.